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Somatostatin Analogue Scintigraphy
A Simple and Sensitive Method for the In Vivo Visualization
of Merkel Cell Tumors and Their Metastases
Dirk J. Kwekkeboom, MD; Anneke M. Hoff, MD; Steven W. J. Lamberts, MD;
H. Yoe Oei, MD; Eric P. Krenning, MD
\s=b\Background.\p=m-\Trabecularcarcinomas of the skin, or Merkel
cell tumors, are aggressive neoplasms that tend to occur in
sun-exposed skin. These tumors frequently metastasize and,
despite therapy, the number of disease-related deaths is high.
Ultrastructurally and immunocytochemically, the majority of
these tumors have neuroendocrine characteristics. Recently,
we described the in vivo visualization of various neuroendo-
crine tumors after injection of a radiolabeled somatostatin
analogue (octreotide). In this study, we report the results of
scintigraphy with radioactive-labeled somatostatin ana-
logues in five patients with Merkel cell tumors.
Observations.\p=m-\Inall four patients in whom tumor was de-
tected using computed tomographic scanning and ultra-
sound, the tumor sites were also demonstrated on octreotide
scintigrams. In one patient, a tumor with a diameter that was
smaller than 0.5 cm could not be detected with octreotide
scintigraphy, computed tomography, or ultrasound. Using
octreotide scintigraphy we found presumed tumor spots in
two patients that were not evident when other techniques
were used.
Conclusions.\p=m-\Octreotidescintigraphy has an equal or
even greater sensitivity than computed tomography and ul-
trasound for detecting Merkel cell tumors and their me-
tastases. Establishing the spread of the disease in this way
may ensure an optimal choice of treatment in patients with
this type of tumor.(Arch Dermatol. 1992;128:818-821)
Trabecular carcinomas of the skin, or Merkel cell tu¬mors, first described in 1972,1 are agressive neo¬
plasms that tend to occur on sun-exposed skin. A high
incidence of spread to regional lymph nodes (45% to
91%) and of distant metastasis (18% to 52%) has been
reported28 (for a review see reference 9). Primary
treatment of these tumors is often limited to local ex¬
cision. Lymph node dissection and postoperative ra¬
diotherapy can be used to treat larger lesions, whereas
recurrences and distant métastases are often treated
with chemotherapy and/or radiotherapy. Neverthe¬
less, depending on the time of follow-up, the incidence
of disease-related death is as high as 35% to 47% in pa¬
tients with Merkel cell tumors.37,8 Early assessment of
the dissemination of the process seems therefore jus¬
tified, as this might change the therapeutic approach to
these tumors.
In the recent literature, several reports have
stressed the neuroendocrine characteristics of Merkel
cell tumors: ultrastructurally they contain secretiongranules,6'7 and immunocytochemical stains are posi¬
tive for neuron-specific enolase (NSE) in the majority
of cases.1013 Recently, we described the in vivo visual¬
ization of various neuroendocrine tumors after injec¬
tion of a somatostatin analogue (octreotide) coupled to
iodine 123.1416 The neuroendocrine features of Merkel
cell tumors prompted us to investigate whether soma¬
tostatin receptors are also present on this type of tu¬
mor, and whether this skin carcinoma and its mé¬
tastases can be visualized in vivo using octreotide
scintigraphy.
PATIENTS AND METHODS
Patients
We studied five patients with Merkel cell tumors in whom
iodine 123 (123I)- or indium 111 (mIn)-labeled octreotide scin¬
tigraphy was performed. Histologie confirmation of the lesion
was obtained in every patient. All patients gave informed
consent to participate in the study, which was approved by
the ethics committee of our hospital.
Accepted for publication October 1, 1991.
From the Departments ofMedicine (Drs Kwekkeboom, Lamberts,
and Krenning) and Nuclear Medicine (Drs Kwekkeboom, Lamberts,
Oei, and Krenning), University Hospital Dijkzigt (Drs Kwekkeboom,
Lamberts, Oei, and Krenning), and the Department of Medicine, Dr
Daniel den Hoed Kliniek (Dr Hoff), Rotterdam, The Netherlands.
Reprints not available.
Downloaded From: http://archderm.jamanetwork.com/ by a Erasmus MC - Univ of Rotterdam User  on 11/20/2014
Methods
The somatostatin analogues tyrosine 3 (Tyr3)-octreotide(204-090) and diethylenetriamine penta-acetic acid-D-
phenylalanine 1 (DTPA-D-Phe^-octreotide (215-811) were
obtained commercially (Sandoz, Basel, Switzerland). Ty¬
rosine 3-octreotide was iodinated as described previously17;
DTPA-D-Phe'-octreotide was coupled to nlIn as described
elsewhere.18
The in vivo visualization of somatostatin receptor-positive
tumors after injection of ^I-Tyr'-octreotide, a radiolabeled
somatostatin analogue, has been described previously.1416
Drawbacks of this in vivo receptor imaging technique are the
limited availability of chemically pure 123I and the high
abdominal background of radioactivity, caused by principal
clearance of this analogue via the liver.19 Therefore, an luIn-
labeled somatostatin analogue has been developed. Because
of its relatively long, effective half-life, lnIn-octreotide is a
radionuclide-coupled somatostatin analogue that can be used
to visualize somatostatin receptor-bearing tumors efficiently
after 24 hours, when interfering background radioactivity is
minimized by renal clearance.19
Planar images were obtained with a large-field-of-view
gamma camera (Counterbalance 3700, Siemens Gammason-
ics, Erlangen, Germany), equipped with a 190-keV parallel-
hole collimator. Static images were obtained 4 and 24 hours
after injection of the 123I-coupled somatostatin analogue, and
24 hours after injection of the mIn-coupled somatostatin an¬
alogue, respectively, because the background radioactivityat
that time is low. To define the tumors as visualized during this
scanning procedure, we used a simple yes-or-no system.
RESULTS
Patient data and results of octreotide scintigraphy
are summarized in the Table. In patients 3 and 5, 123I-
Tyi^-octreotide (565 to 570 MBq) was injected, and in
the other patients, mIn-DTPA-octreotide (262 to 328
MBq) was injected. Case reports and the outcomes of
visualization techniques are listed below.
Patient 1 had her right little finger amputated 2
years previously because of a trabecular carcinoma of
the skin. Now the tumor had recurred at the site of the
amputation. At physical examination, tumor was also
suspected at the right elbow. In addition, the patient
had an enlarged lymph node in the right axilla and her
Patient Data and Results of Octreotide Scintigraphy
Patient No. Sex Age, y Tumor Sites Sites on Octreotide Scintigraphy
1/F/53 Finger, elbow, axilla, liver Finger, forearm, elbow, axilla, lung hilum
2/M/49 Oropharynx None
3/M/63 Sinus and órbita, abdomen Sinus and órbita, abdomen
4/M/46 Supraclavicular lymph nodes Supraclavicular spots
5/M/79 Head Head and parotic region
Fig 1.—Scintigraphy of the anterior skull of patient 3,24 hours
after injection of iodine 123-tyrosine 3-octreotide. Th indi¬
cates thyroid; T, tumor in the left órbita and sinuses.
Fig 2.—Scintigraphy of the head and neck of patient 5, 24
hours after injection of iodine 123-tyrosine 3-octreotide. T in¬
dicates primary tumor and spots in the parotic region. Note the
physiologic accumulation in the pituitary, centrally in the skull.
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liver was enlarged. Computed tomography of the tho¬
rax and abdomen showed multiple small métastases in
the liver. A biopsy specimen of the lesion on the elbow
contained a small-cell tumor, which was diagnosed as
Merkel cell carcinoma. Stains were negative for NSE
and chromogranin. Octreotide scintigraphy showed
accumulation of radioactivity at the site of the primary
tumor; stringlike spots in the right hand, forearm, el¬
bow, and axilla; and a spot in the right pulmonary
hilum. The distribution of radioactivity in the liver
showed no irregularities. The patient was treated with
chemotherapy and had a complete remission after 3
months. On octreotide scanning at this time, the sites
of abnormal radioactive accumulation had disappeared.
Patient 2 had undergone an excision of a trabecular
carcinoma of the buttock 2 years previously. An
enlarged inguinal lymph node that had appeared 5
months later had also been removed. Both tumors were
NSE positive. At the present time, the patient had
complaints of swallowing. Computed tomography of
the pharynx and abdomen, ultrasound of the neck, and
octreotide scintigraphy revealed no abnormalities. At
inspection of the pharynx, however, a small exophytic
tumor with a diameter of less than 0.5 cm was seen.
Histologie examination of the biopsy specimen and
positive stains for NSE confirmed the diagnosis of
Merkel cell tumor.
Patient 3 had a tumor of the lower eyelid removed 3.5
years previously. Two irradical reexcisions of the
recurring tumor ensued. At that time, the tumor was
diagnosed as a basal cell carcinoma. When the tumor
recurred half a year later, it was diagnosed as an NSE-
and chromogranin-positive Merkel cell tumor. Radio¬
therapy resulted in a complete remission. At the
present time, the patient had pain in the left eye, which
had protruded. Ultrasound revealed enlarged lymph
nodes in the neck and abdomen. The biopsy specimens
of these lymph nodes were tumor positive. A debulk-
ing operation of the tumor in the sinuses and órbita and
lymph node dissection of the neck were performed.
Two months later the tumor rest in the left eye and si¬
nuses was visible on computed tomographic scan and
octreotide scintigrams (Fig 1). Fifteen minutes after
injection of 123I-Tyr3-octreotide, an abnormal accumu¬
lation of radioactivity was noted in the upper abdomen.
This had disappeared on the scintigrams obtained 24
hours after injection. Eleven months later, the patient
died of tumor growth in the abdomen.
In patient 4, a chromogranin-positive trabecular
carcinoma of the neck and a recurrent tumor at the
same spot were excised 14 and 4 months, respectively,
before octreotide scintigraphy was performed. A
lymph node metastasis in the neck was removed 1
month before scintigraphy was performed. At physical
examination, two mobile supraclavicular lymph nodes
were observed. Octreotide scintigraphy revealed ac¬
cumulation of radioactivity at these sites.
Patient 5 suffered from chronic lymphatic leukemia
and a recurrence of an NSE-positive Merkel cell tumor
of the forehead. Five months previously, the trabecu¬
lar carcinoma had been partially removed. Before scin¬
tigraphy, a biopsy was performed on a tumor that
contained a preauricular lymph node. Computed to¬
mography of the head showed a soft-tissue tumor. Oc¬
treotide scintigraphy revealed spots on the site of the
tumor and two spots behind the ear, suggestive of mé¬
tastases (Fig 2). At physical examination 1 month later,
enlarged lymph nodes were found behind the ear.
COMMENT
Local recurrence and metastasis after initial treat¬
ment of Merkel cell tumors are frequent.19'20"23 In our
series, distant spread after initial surgical removal of
the tumor occurred in all five patients. Also, multifo-
cality of the tumor at or about the time of diagnosis is
not infrequent.8,24,26 Therefore, accurate localization
and staging of the tumor should be performed in everypatient, as this might influence the choice of treatment:
excision, radiotherapy, chemotherapy, or combinations
of these. In vivo visualization of these tumors using oc¬
treotide scintigraphy may be of help in this respect, as
will be discussed below.
In all four patients in whom tumor was indicated by
computed tomography and ultrasound, the tumor sites
were also demonstrated on octreotide scintigrams. In
one patient, no tumor could be detected with octreotide
scintigraphy, CT, or ultrasound. The lesion was prob¬
ably too small to be detected with any of these
techniques. Multiple small métastases in the liver of
one patient were not observed on octreotide scinti¬
grams, perhaps because the lesions were too small to
be detected or because they accumulated about as
much radioactivity as did the normal liver tissue. Un¬
fortunately, technetium 99m colloid scintigraphy was
not performed in this patient, so this problem could not
be addressed. Using octreotide scintigraphy we found
presumed tumor spots that were not detected by other
techniques in two patients (patients 1 and 5). In one of
these patients (No. 5), enlarged lymph nodes, probably
caused by tumor métastases, developed at the site of
the spots that had been observed on the octreotide
scintigrams 1 month previously. In four patients, the
lesions demonstrated on CT and ultrasound scans
coincided with spots of accumulation of labeled oc¬
treotide. In one patient, sites of abnormal accumulation
of radioactivity that were present before treatment
had disappeared when a complete remission after che¬
motherapy had been reached.
Merkel cell carcinoma, also termed neuroendocrine
carcinoma of the skin,3 or cutaneous apudoma,21 is a
rare skin tumor. Electron microscopy may reveal
secretion granules in these tumors,6,7 and staining for
NSE is positive in the majority of cases.1013 Our data
suggest that Merkel cell tumors, like other neuroendo¬
crine tumors that can be visualized using in vivo
octreotide scintigraphy, ie, carcinoids, paragangliomas,
and endocrine pancreatic tumors,1410 contain binding
sites for somatostatin. Whether other somatostatin
analogues coupled to radiotherapeutical isotopes can be
used in the future treatment of disseminated Merkel
cell tumors is at this moment speculative.
Regional lymph node dissection and radiotherapy
are generally not applied for Merkel cell tumors that
have not disseminated.3 However, the metastatic po-
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tential of these carcinomas mandates that an early and
accurate staging be made. From our data we conclude
that octreotide scintigraphy has an equal or greater
sensitivity for detecting Merkel cell tumors and their
métastases than do CT scanning and ultrasound. If oc¬
treotide scintigraphy were performed in patients with
Merkel cell tumors, the sites of abnormal accumulation
of radioactivity could thereafter be visualized using CT
scanning or ultrasound, and then undergo biopsy. Es¬
tablishing the extent of the disease in this way may
ensure an optimal choice of treatment for these tumors.
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ARCHIVES OF OPHTHALMOLOGY
The Ultrastructural Defect in Conjunctiva From a Case ofRecessive Dystrophie
Epidermolysis Hullosa
Iwamoto M, Haik BG, Iwamoto T, et al. (Arch Ophthalmol. 1991;109:1382-1386)
The eye findings in four cases of recessive dystrophic epidermolysis bullosa are presented.
In the one case studied, the same defect noted in the skin of patients with recessive dystro¬
phic epidermolysis bullosa, absence of anchoring fibrils, was demonstrated in a biopsy spec¬
imen from the conjunctiva.
Large-cell Acanthoma of the Eyelid: Report of Two Cases
Chevez P, Patrinely JR, Font RL. (Arch Ophthalmol. 1991;109:1433-1434)
The authors report the first description of this lesion on the eyelids. This uncommon tu¬
mor is characterized clinically as a slightly scaling, flat-topped lesion that occurs predomi¬
nantly on sun-exposed skin. The lesions are generally misdiagnosed as actinic kératoses. An
excellent color clinical photograph of one of the two lesions is presented.
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